Biotechnology
The latest news about Biotechnology: headlines, AI summaries and the full story from every source.
- Araceli Biosciences Secures $4.5 Million Financing Round Supported by Jeff Swickard
- Alphabet's DeepMind Unveils AlphaGenome 2 AI Model for DNA Analysis
- Capricor Therapeutics Shares Rise Following JonesTrading Upgrade Ahead of FDA Decision
- Protagenic Therapeutics Announces Private Placement to Raise Up to $5 Million
- Amgen Shares Decline Following Late-Stage Trial Results for Sjögren's Disease Drug
- Cellectar Reports Q3 2026 Financial Results and Clinical Progress for iopofosine I-131
- Capricor Reports Q3 2026 Financial Results and HOPE-3 Clinical Trial Data
- Capricor Therapeutics Updates Deramiocel BLA Timeline and Manufacturing Validation Goals
- GeneDx Holdings Shares Drop 16.6% Following Lowered Growth Targets
- Liquidia Corporation Shares Rise 7% Following Q3 Results and Litigation Settlement
- Hemab Reports Q3 2026 Financial Results and Clinical Pipeline Updates
- MiNK Therapeutics Scheduled to Report Q3 2026 Earnings
- Scholar Rock Anticipates CHMP Opinion in 2027 Following ISEMBYLD FDA Approval
- AstraZeneca Acquires Preclinical Biotech Omniose to Enhance Vaccine Platform
- Immatics Reports Q3 Financial Results and Cash Runway Extension
- Autolus Therapeutics Reports Q3 Revenue Beat and Upward 2026 Product Guidance
- Olema Pharmaceuticals Reports Third Quarter GAAP EPS Miss
- Coherus Oncology Announces Workforce Reductions and Strategic Clinical Shift
- AbCellera Reports Q3 2026 Results and Positive Phase II Data for ABCL635
- AbCellera Plans Late-Stage Development for ABCL635 in 2027 Following Positive Phase II Results
- Immunovant Reports Q2 2026 Financial Results and IMVT-1402 Clinical Data
- IQVIA Reports Strong Q3 2026 Results with Record Clinical Bookings and Raised Guidance
- Ionis Lowers TRYNGOLZA Revenue Guidance and Delays Cash Flow Breakeven to 2029
- Annexon Biosciences Reports Third Quarter GAAP EPS of -$0.25 and Updates Clinical Trial Progress
- TG Therapeutics Raises 2026 Revenue Guidance to $1 Billion Amid BRIUMVI Growth
- Ionis Pharmaceuticals Projects 2026 Revenue Between $875M and $900M Amid Lowered TRYNGOLZA Outlook
- William Blair Initiates Coverage on Solid Biosciences with Outperform Rating
- Bicara Therapeutics Announces Mid-2027 Interim Analysis Timeline and Cash Runway Extension
- Johnson & Johnson Venture Fund Participates in $100 Million Financing Round for Delix Therapeutics
- Compugen Expects MAIA-Ovarian Clinical Data by Q1 2027 and Maintains Funding Through 2029
- TG Therapeutics Reports Q3 Revenue Beat and Raises Full-Year 2026 Guidance
- Moderna Upgrades 2026 Revenue Guidance Following Positive Phase 3 Cancer Vaccine Results
- Edgewise Therapeutics Shares Rise on Takeover Speculation
- CytomX Therapeutics Projects Varseta-M Registrational Study for First Half of 2027
- Verastem Oncology Reports Q3 Revenue and Outlines Long-Term Funding Strategy
- Midday Market Update: Tech and Semiconductor Stocks Experience High Volatility
- Edgewise Therapeutics Shares Rise Following Reports of Potential Takeover Interest
- Elutia Plans FDA Submission for NXT-41X This Quarter Following Successful Clinical Study
- Rhythm Pharmaceuticals Shares Rise Following Reports of Potential Second Bidder
- Halozyme Therapeutics Shares Drop Following Leerink Partners Downgrade
- Moderna Exceeds Q3 Estimates and Raises 2026 Revenue Growth Guidance
- Protagonist Therapeutics Reports Q3 Earnings Beat with Significant Revenue Growth
- Tyra Biosciences Announces Participation in Upcoming Healthcare Investor Conferences
- Cognition Therapeutics Reports Q3 2026 Financial Results and Phase III Trial Updates
- Nautilus Announces 2026 Revenue Forecast Increase and Proteoform Assay Roadmap
- Regenxbio Plans RGX-202 BLA Filing for Q1 2027 and Maintains Cash Runway Through Q4 2027
- ADMA Biologics Shares Surge Following Third Quarter Earnings Beat
- OnKure Therapeutics Reports Q3 GAAP EPS of -$0.36 and Strong Cash Runway
- OPKO Health Reports Q3 2026 Revenue Growth and Completes BioReference Asset Sale
- Nanoscope Therapeutics Appoints Damon Daulerio as Executive Director of Regulatory Affairs